Atossa Genetics Inc (ATOS) 2.42 $ATOS
Edison Issues Flash Update on Atossa Genetics (ATOS)
PR Newswire - Fri Sep 02, 12:54PM CDT
Atossa Genetics plans to raise up to $2.9m in an equity offering of 1.15m shares, priced at $2.50 per share (a 29% discount to the 30 August 2016 market close of $3.45). The proceeds should help fund Atossa's two active breast cancer therapeutic development programs, intraductal microcatheter (IDMC) administered fulvestrant and oral endoxifen.
ATOS: 2.42 (+0.01)
Atossa Genetics, Inc. Prices Underwritten Public Offering of 1,150,000 Common Shares
Marketwire Canada - Wed Aug 31, 5:30AM CDT
SEATTLE, WA--(Marketwired - Aug 31, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS), today announced the pricing of an underwritten public offering of 1,150,000 shares of its common stock at a price to the public of $2.50 per share. The gross proceeds to Atossa Genetics, Inc., from this offering are expected to be approximately $2,875,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Atossa Genetics, Inc. has granted the underwriters a 45-day option to purchase up to an additional 172,500 shares of common stock to cover over-allotments, if any. The offering is expected to close on September 6, 2016, subject to customary closing conditions.
ATOS: 2.42 (+0.01)
Atossa Genetics Inc. Announces Proposed Public Offering of Common Stock
Marketwired - Tue Aug 30, 3:01PM CDT
SEATTLE, WA--(Marketwired - Aug 30, 2016) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it intends to offer for sale shares of its common stock in an underwritten public offering. The company intends to use the net proceeds from this offering for working capital and to fund other general corporate purposes, including funding the costs of clinical trials. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ATOS: 2.42 (+0.01)
Atossa Genetics Announces Reverse Stock Split
Marketwired - Thu Aug 25, 11:00AM CDT
1:15 Reverse Stock Split Effective August 26, 2016
ATOS: 2.42 (+0.01)
Atossa Genetics Announces Second Quarter 2016 Financial Results and Provides Company Update
Marketwired - Fri Aug 12, 7:00AM CDT
Conference Call to Be Held Monday, August 15, 2016 at 4:30 pm Eastern Time
ATOS: 2.42 (+0.01)
Atossa Genetics to Provide Company Update and Discuss Second Quarter Financial Results on Conference Call on Monday, August 15, 2016
Marketwired - Wed Aug 10, 7:00AM CDT
SEATTLE, WA--(Marketwired - Aug 10, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that it will provide a Company update and discuss second quarter 2016 financial results on Monday, August 15, 2016 at 4:30 pm eastern time. Following management's formal remarks, there will be a question and answer session.
ATOS: 2.42 (+0.01)
Atossa Genetics Settles Litigation With Besins Healthcare
Marketwire Canada - Fri Aug 05, 7:00AM CDT
Atossa to Receive Cash Payment of $1.76 Million
ATOS: 2.42 (+0.01)
Atossa Genetics Initiates Additional Drug Development Program
Marketwired - Tue Jun 07, 7:01AM CDT
Oral Endoxifen for Patients Refractory to Tamoxifen
ATOS: 2.42 (+0.01)
Atossa Genetics to Present at 6th Annual LD Micro Invitational Conference on June 7th, 2016
ACCESSWIRE - Tue May 31, 7:01AM CDT
SEATTLE, WA / ACCESSWIRE / May 31, 2016 / Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that Dr. Steven Quay, President and CEO, would be a featured presenter at the 6th annual LD Micro Invitational on June 7th, 2016 at 9:30am PST, Track 3 at the Luxe Sunset Hotel in Los Angeles, CA. Management will also be available for one-on-one meetings on June 7 and 8, 2016.
ATOS: 2.42 (+0.01)
Atossa Genetics Announces $10 Million At-the-Market Common Stock Purchase Agreement With Aspire Capital Fund, LLC
Marketwired - Fri May 27, 7:00AM CDT
SEATTLE, WA--(Marketwired - May 27, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that it has entered into a $10 million stock purchase agreement with Aspire Capital Fund, LLC. Under terms of the agreement, after the SEC declares the registration statement related to the transaction effective, Aspire has committed to purchase up to $10 million of Atossa's common stock over 30 months, based on prevailing market prices over a period preceding each sale.
ATOS: 2.42 (+0.01)
Why Investors Still See Value in Alkermes, AMAG Pharmaceuticals, IDEXX Laboratories and Atossa Genetics?
PR Newswire - Thu May 19, 7:50AM CDT
The equities market is never short of surprises, and one sector that is always abounding of surprises is without doubt the Healthcare space. ActiveWallSt.com has uncovered four stocks in the Healthcare sector ahead of today's trading session: Alkermes PLC (NASDAQ: ALKS), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), and Atossa Genetics Inc. (NASDAQ: ATOS). Sign up for your complimentary alerts at:
ATOS: 2.42 (+0.01), AMAG: 23.66 (-0.05), IDXX: 114.09 (+0.93), ALKS: 45.12 (+0.38)
Atossa Genetics Announces First Quarter 2016 Financial Results and Provides Company Update
Marketwire Canada - Thu May 05, 3:01PM CDT
Conference Call to Be Held Today at 4:30 pm Eastern Time
ATOS: 2.42 (+0.01)
Edison Issues Flash Update on Atossa Genetics (ATOS)
PR Newswire - Fri Sep 02, 12:54PM CDT
Atossa Genetics plans to raise up to $2.9m in an equity offering of 1.15m shares, priced at $2.50 per share (a 29% discount to the 30 August 2016 market close of $3.45). The proceeds should help fund Atossa's two active breast cancer therapeutic development programs, intraductal microcatheter (IDMC) administered fulvestrant and oral endoxifen.
ATOS: 2.42 (+0.01)
Atossa Genetics, Inc. Prices Underwritten Public Offering of 1,150,000 Common Shares
Marketwire Canada - Wed Aug 31, 5:30AM CDT
SEATTLE, WA--(Marketwired - Aug 31, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS), today announced the pricing of an underwritten public offering of 1,150,000 shares of its common stock at a price to the public of $2.50 per share. The gross proceeds to Atossa Genetics, Inc., from this offering are expected to be approximately $2,875,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Atossa Genetics, Inc. has granted the underwriters a 45-day option to purchase up to an additional 172,500 shares of common stock to cover over-allotments, if any. The offering is expected to close on September 6, 2016, subject to customary closing conditions.
ATOS: 2.42 (+0.01)
Atossa Genetics Inc. Announces Proposed Public Offering of Common Stock
Marketwired - Tue Aug 30, 3:01PM CDT
SEATTLE, WA--(Marketwired - Aug 30, 2016) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it intends to offer for sale shares of its common stock in an underwritten public offering. The company intends to use the net proceeds from this offering for working capital and to fund other general corporate purposes, including funding the costs of clinical trials. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ATOS: 2.42 (+0.01)
Atossa Genetics Announces Reverse Stock Split
Marketwired - Thu Aug 25, 11:00AM CDT
1:15 Reverse Stock Split Effective August 26, 2016
ATOS: 2.42 (+0.01)
Atossa Genetics Announces Second Quarter 2016 Financial Results and Provides Company Update
Marketwired - Fri Aug 12, 7:00AM CDT
Conference Call to Be Held Monday, August 15, 2016 at 4:30 pm Eastern Time
ATOS: 2.42 (+0.01)
Atossa Genetics to Provide Company Update and Discuss Second Quarter Financial Results on Conference Call on Monday, August 15, 2016
Marketwired - Wed Aug 10, 7:00AM CDT
SEATTLE, WA--(Marketwired - Aug 10, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that it will provide a Company update and discuss second quarter 2016 financial results on Monday, August 15, 2016 at 4:30 pm eastern time. Following management's formal remarks, there will be a question and answer session.
ATOS: 2.42 (+0.01)
Atossa Genetics Settles Litigation With Besins Healthcare
Marketwire Canada - Fri Aug 05, 7:00AM CDT
Atossa to Receive Cash Payment of $1.76 Million
ATOS: 2.42 (+0.01)
Atossa Genetics Initiates Additional Drug Development Program
Marketwired - Tue Jun 07, 7:01AM CDT
Oral Endoxifen for Patients Refractory to Tamoxifen
ATOS: 2.42 (+0.01)
Atossa Genetics to Present at 6th Annual LD Micro Invitational Conference on June 7th, 2016
ACCESSWIRE - Tue May 31, 7:01AM CDT
SEATTLE, WA / ACCESSWIRE / May 31, 2016 / Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that Dr. Steven Quay, President and CEO, would be a featured presenter at the 6th annual LD Micro Invitational on June 7th, 2016 at 9:30am PST, Track 3 at the Luxe Sunset Hotel in Los Angeles, CA. Management will also be available for one-on-one meetings on June 7 and 8, 2016.
ATOS: 2.42 (+0.01)
Atossa Genetics Announces $10 Million At-the-Market Common Stock Purchase Agreement With Aspire Capital Fund, LLC
Marketwired - Fri May 27, 7:00AM CDT
SEATTLE, WA--(Marketwired - May 27, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that it has entered into a $10 million stock purchase agreement with Aspire Capital Fund, LLC. Under terms of the agreement, after the SEC declares the registration statement related to the transaction effective, Aspire has committed to purchase up to $10 million of Atossa's common stock over 30 months, based on prevailing market prices over a period preceding each sale.
ATOS: 2.42 (+0.01)
Why Investors Still See Value in Alkermes, AMAG Pharmaceuticals, IDEXX Laboratories and Atossa Genetics?
PR Newswire - Thu May 19, 7:50AM CDT
The equities market is never short of surprises, and one sector that is always abounding of surprises is without doubt the Healthcare space. ActiveWallSt.com has uncovered four stocks in the Healthcare sector ahead of today's trading session: Alkermes PLC (NASDAQ: ALKS), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), and Atossa Genetics Inc. (NASDAQ: ATOS). Sign up for your complimentary alerts at:
ATOS: 2.42 (+0.01), AMAG: 23.66 (-0.05), IDXX: 114.09 (+0.93), ALKS: 45.12 (+0.38)
Atossa Genetics Announces First Quarter 2016 Financial Results and Provides Company Update
Marketwire Canada - Thu May 05, 3:01PM CDT
Conference Call to Be Held Today at 4:30 pm Eastern Time
ATOS: 2.42 (+0.01)
